After consultation with FDA, Polaris will follow Data and Safety Monitoring Board’s (DSMB) recommendation to stop Phase III study in lung mesothelioma due to current success and difficulty in continued enrollment
Polaris-Press Release-FDA Response to DSMB Recommendation-5 August 2021 Read More »
Based on the data at the interim analysis of Feb 25, 2021, it is estimated that the chance for success, that the survival benefit of ADI PEG-20 over the control group is statistically significant at the end of the trial, will be greater than 80%.
Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area, and Polaris Group, a developer of novel treatments for cancer, announced today they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing.
Polaris Group signs collaboration agreement with Nanotein Technologies, Inc. Read More »
Taipei, September 17, 2020 – Polaris Group announced today that the first patient has been dosed in a phase 1B trial of ADI‑PEG 20 in combination with Radiotherapy and Temozolomide for the treatment of Newly Diagnosed Glioblastoma Multiforme (GBM). The Lead Investigator is Dr. Wei from Linkou Chang Gung Memorial Hospital. There will be 26 patients enrolled in this phase 1B trial.
Polaris announces to enroll the first patient of Phase IB Clinical Trial in GBM Read More »
